{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:51:27Z","timestamp":1791219087422,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurologic Disorders and Stroke","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["R01NS110519"],"award-info":[{"award-number":["R01NS110519"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["UG3NS131096"],"award-info":[{"award-number":["UG3NS131096"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32AI055433"],"award-info":[{"award-number":["T32AI055433"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The EnACT trial was a phase 2 randomized clinical trial conducted in Uganda, which evaluated a novel orally delivered lipid nanocrystal (LNC) amphotericin B in combination with flucytosine for the treatment of cryptococcal meningitis. When flucytosine (5FC) is used as monotherapy in cryptococcosis, 5FC can induce resistant Cryptococcus mutants. Oral amphotericin B uses a novel drug delivery mechanism, and we assessed whether resistance to 5FC develops during oral LNC\u2013amphotericin B therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We enrolled Ugandans with HIV diagnosed with cryptococcal meningitis and who were randomized to receive 5FC and either standard intravenous (IV) amphotericin B or oral LNC\u2013amphotericin B. We used broth microdilution to measure the minimum inhibitory concentration (MIC) of the first and last cryptococcal isolates in each participant. Breakpoints are inferred from 5FC in Candida albicans. We measured cerebral spinal fluid (CSF) 5FC concentrations by liquid chromatography and tandem mass spectrometry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Cryptococcus 5FC MIC50 was 4\u2005\u00b5g\/mL, and MIC90 was 8\u2005\u00b5g\/mL. After 2 weeks of therapy, there was no evidence of 5FC resistance developing, defined as a &amp;gt;4-fold change in susceptibility in any Cryptococcus isolate tested. The median CSF 5FC concentration to MIC ratio (interquartile range) was 3.0 (1.7\u20135.5)\u2005\u00b5g\/mL. There was no association between 5FC\/MIC ratio and early fungicidal activity of the quantitative rate of CSF yeast clearance (R2 = 0.004; P = .63).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>There is no evidence of baseline resistance to 5FC or incident resistance during combination therapy with oral or IV amphotericin B in Uganda. Oral amphotericin B can safely be used in combination with 5FC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofad596","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T21:36:35Z","timestamp":1701293795000},"source":"Crossref","is-referenced-by-count":8,"title":["5-Flucytosine Longitudinal Antifungal Susceptibility Testing of <i>Cryptococcus neoformans<\/i>: A Substudy of the EnACT Trial Testing Oral Amphotericin"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7226-3075","authenticated-orcid":false,"given":"Thomas C","family":"McHale","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Minnesota , Minneapolis, Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Akampurira","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, Makerere University , Kampala , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot S","family":"Gerlach","sequence":"additional","affiliation":[{"name":"Department of Microbiology & Immunology, University of Minnesota , Minneapolis, Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atukunda","family":"Mucunguzi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, Makerere University , Kampala , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5513-5509","authenticated-orcid":false,"given":"Melanie R","family":"Nicol","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, University of Minnesota , Minneapolis, Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darlisha A","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Minnesota , Minneapolis, Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Microbiology & Immunology, University of Minnesota , Minneapolis, Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2676-838X","authenticated-orcid":false,"given":"Tihana","family":"Bicanic","sequence":"additional","affiliation":[{"name":"Institute of Infection and Immunity, St Georges, University of London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Fieberg","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, School of Public Health, University of Minnesota , Minneapolis, Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biyue","family":"Dai","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, School of Public Health, University of Minnesota , Minneapolis, Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8854-0321","authenticated-orcid":false,"given":"David B","family":"Meya","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Minnesota , Minneapolis, Minnesota , USA"},{"name":"Infectious Diseases Institute, Makerere University , Kampala , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Boulware","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Minnesota , Minneapolis, Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ENACT Trial Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enock","family":"Kagimu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdu K","family":"Musubire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Tugume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Ssebambulidde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kasibante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Nsangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Mugabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Gakuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kimuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick","family":"Kasozi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan","family":"Namombwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Turyasingura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris K","family":"Rutakingirwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Mpoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enos","family":"Kigozi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Muzoora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb P","family":"Skipper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darlisha A","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy H","family":"Hullsiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Abassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmus","family":"Tukundane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane F","family":"Ndyetukira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Ahimbisibwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisat","family":"Sadiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Kugonza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifa","family":"Nabbale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeo","family":"Kiiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Namudde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Luggya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kwizera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Okiror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Babirye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Nanteza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Mulwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhona","family":"Muyise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kisembo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Luswata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Namujju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Laker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Walukaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minda","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Engen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abduljewad","family":"Wele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Rwomushana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mable","family":"Kabahubya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ssemusu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Mwesigye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Rukundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Jjunju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"key":"2023122900463328000_ofad596-B1","doi-asserted-by":"crossref","first-page":"ofz419","DOI":"10.1093\/ofid\/ofz419","article-title":"The changing epidemiology of HIV-associated adult meningitis, Uganda 2015\u20132017","volume":"6","author":"Ellis","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2023122900463328000_ofad596-B2","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1097\/QAI.0b013e31828e1e56","article-title":"Cost-effective diagnostic checklists for meningitis in resource limited settings","volume":"63","author":"Durski","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023122900463328000_ofad596-B3","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","article-title":"Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis","volume":"17","author":"Rajasingham","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2023122900463328000_ofad596-B4","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/S1473-3099(22)00499-6","article-title":"The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis","volume":"22","author":"Rajasingham","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2023122900463328000_ofad596-B5","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1086\/587667","article-title":"Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy","volume":"46","author":"Kambugu","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2023122900463328000_ofad596-B6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/QAI.0000000000002095","article-title":"Mortality following cryptococcal infection in the modern antiretroviral therapy era","volume":"82","author":"Hevey","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023122900463328000_ofad596-B7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/cid\/cit794","article-title":"Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: implications for improving outcomes","volume":"58","author":"Jarvis","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2023122900463328000_ofad596-B8","volume-title":"Guidelines for the Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children","author":"World Health Organization","year":"2018"},{"key":"2023122900463328000_ofad596-B9","volume-title":"Guidelines for Diagnosing, Preventing and Managing Cryptococcal Disease Among Adults, Adolescents and Children Living With HIV","author":"World Health Organization","year":"2022"},{"key":"2023122900463328000_ofad596-B10","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJMoa1710922","article-title":"Antifungal combinations for treatment of cryptococcal meningitis in Africa","volume":"378","author":"Molloy","year":"2018","journal-title":"New Engl J Med"},{"key":"2023122900463328000_ofad596-B11","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa2111904","article-title":"Single-dose liposomal amphotericin B treatment for cryptococcal meningitis","volume":"386","author":"Jarvis","year":"2022","journal-title":"N Engl J Med"},{"key":"2023122900463328000_ofad596-B12","doi-asserted-by":"crossref","first-page":"e00724","DOI":"10.1128\/mBio.00724-19","article-title":"Efficacy of oral encochleated amphotericin B in a mouse model of cryptococcal meningoencephalitis","volume":"10","author":"Lu","year":"2019","journal-title":"mBio"},{"key":"2023122900463328000_ofad596-B13","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/cid\/ciad440","article-title":"Oral lipid nanocrystal amphotericin B for cryptococcal meningitis: a randomized clinical trial","volume":"77","author":"Boulware","year":"2023","journal-title":"Clin Infect Dis."},{"key":"2023122900463328000_ofad596-B14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1086\/524071","article-title":"Resistance to antifungal agents: mechanisms and clinical impact","volume":"46","author":"Kanafani","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2023122900463328000_ofad596-B15","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1128\/AAC.47.10.3361-3364.2003","article-title":"In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates","volume":"47","author":"Schwarz","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2023122900463328000_ofad596-B16","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1128\/AAC.39.8.1691","article-title":"In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans","volume":"39","author":"Nguyen","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"2023122900463328000_ofad596-B17","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1128\/AAC.01188-06","article-title":"Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis","volume":"51","author":"Brouwer","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2023122900463328000_ofad596-B18","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/jac\/dkad038","article-title":"Population pharmacokinetics and CSF penetration of flucytosine in adults with HIV-associated cryptococcal meningoencephalitis","volume":"78","author":"Stott","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2023122900463328000_ofad596-B19","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1128\/AAC.00369-06","article-title":"Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and impact of the MIC, growth rate, and resistance genotype on the antifungal effect","volume":"50","author":"Hope","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2023122900463328000_ofad596-B20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1472-8206.2002.00064.x","article-title":"5-fluorocytosine-related bone-marrow depression and conversion to fluorouracil: a pilot study","volume":"16","author":"Vermes","year":"2002","journal-title":"Fundam Clin Pharmacol"},{"key":"2023122900463328000_ofad596-B21","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1038\/s41467-021-23745-1","article-title":"Moderate levels of 5-fluorocytosine cause the emergence of high frequency resistance in cryptococci","volume":"12","author":"Chang","year":"2021","journal-title":"Nat Commun"},{"key":"2023122900463328000_ofad596-B22","article-title":"Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts","author":"Arendrup","year":"2020","journal-title":"The European Committee on Antimicrobial Susceptibility Testing Antifungal MIC Method for Yeasts, Version 7.3"},{"key":"2023122900463328000_ofad596-B23","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1128\/AAC.06252-11","article-title":"Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine","volume":"56","author":"Espinel-Ingroff","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2023122900463328000_ofad596-B24","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/cid\/ciaa016","article-title":"Cerebrospinal fluid early fungicidal activity as a surrogate endpoint for cryptococcal meningitis survival in clinical trials","volume":"71","author":"Pullen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023122900463328000_ofad596-B25","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2021"},{"key":"2023122900463328000_ofad596-B26","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/jcm.23.2.298-301.1986","article-title":"Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B","volume":"23","author":"Calhoun","year":"1986","journal-title":"J Clin Microbiol"},{"key":"2023122900463328000_ofad596-B27","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1128\/AAC.31.9.1343","article-title":"Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods","volume":"31","author":"Galgiani","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"2023122900463328000_ofad596-B28","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1128\/JCM.43.5.2163-2167.2005","article-title":"Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004)","volume":"43","author":"Pfaller","year":"2005","journal-title":"J Clin Microbiol"},{"key":"2023122900463328000_ofad596-B29","first-page":"158","article-title":"5-fluorocytosine\u2014current status with special references to mode of action and drug resistance","volume":"4","author":"Polak","year":"1977","journal-title":"Contrib Microbiol Immunol"},{"key":"2023122900463328000_ofad596-B30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000221854","article-title":"Mode of action of 5-fluorocytosine and mechanisms of resistance","volume":"21","author":"Polak","year":"2009","journal-title":"Chemotherapy"},{"key":"2023122900463328000_ofad596-B31","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1086\/507895","article-title":"Symptomatic relapse of HIV-associated cryptococcal meningitis after initial huconazole monotherapy: the role of fluconazole resistance and immune reconstitution","volume":"43","author":"Bicanic","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2023122900463328000_ofad596-B32","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.mmcr.2017.11.004","article-title":"Emerging fluconazole resistance: implications for the management of cryptococcal meningitis","volume":"19","author":"Mpoza","year":"2017","journal-title":"Med Mycol Case Rep"},{"key":"2023122900463328000_ofad596-B33","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/myc.12747","article-title":"A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species","volume":"61","author":"Bongomin","year":"2018","journal-title":"Mycoses"},{"key":"2023122900463328000_ofad596-B34","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/infdis\/jix033","article-title":"Differences in immunologic factors among patients presenting with altered mental status during cryptococcal meningitis","volume":"215","author":"Lofgren","year":"2017","journal-title":"J Infect Dis"},{"key":"2023122900463328000_ofad596-B35","doi-asserted-by":"crossref","first-page":"e00069-19","DOI":"10.1128\/CMR.00069-19","article-title":"Antifungal susceptibility testing: current approaches","volume":"33","author":"Berkow","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"2023122900463328000_ofad596-B36","doi-asserted-by":"crossref","first-page":"ofz369","DOI":"10.1093\/ofid\/ofz369","article-title":"Minimum inhibitory concentration distribution of fluconazole against Cryptococcus species and the fluconazole exposure prediction model","volume":"6","author":"Chesdachai","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2023122900463328000_ofad596-B37","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1128\/AAC.00446-06","article-title":"Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans","volume":"51","author":"Schwarz","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2023122900463328000_ofad596-B38","doi-asserted-by":"crossref","first-page":"e04783-22","DOI":"10.1128\/spectrum.04783-22","article-title":"Carbon dioxide potentiates flucytosine susceptibility in Cryptococcus neoformans","volume":"11","author":"Jezewski","year":"2023","journal-title":"Microbiol Spectrum"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad596\/53940172\/ofad596.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/12\/ofad596\/54914601\/ofad596.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/12\/ofad596\/54914601\/ofad596.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T01:08:05Z","timestamp":1703812085000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad596\/7455708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad596","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,11,29]]},"article-number":"ofad596"}}